| Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients A Vijenthira, IY Gong, TA Fox, S Booth, G Cook, B Fattizzo, F Martín-Moro, ... Blood, The Journal of the American Society of Hematology 136 (25), 2881-2892, 2020 | 597 | 2020 |
| Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia LA Carvajal, DB Neriah, A Senecal, L Benard, V Thiruthuvanathan, ... Science translational medicine 10 (436), eaao3003, 2018 | 213 | 2018 |
| miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling TD Bhagat, L Zhou, L Sokol, R Kessel, G Caceres, K Gundabolu, ... Blood, The Journal of the American Society of Hematology 121 (15), 2875-2881, 2013 | 147 | 2013 |
| Pharmacological inhibition of the transcription factor PU. 1 in leukemia I Antony-Debré, A Paul, J Leite, K Mitchell, HM Kim, LA Carvajal, ... The Journal of clinical investigation 127 (12), 4297-4313, 2017 | 107 | 2017 |
| IL1RAP potentiates multiple oncogenic signaling pathways in AML K Mitchell, L Barreyro, TI Todorova, SJ Taylor, I Antony-Debré, ... Journal of Experimental Medicine 215 (6), 1709-1727, 2018 | 80 | 2018 |
| North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies UA Shah, EY Chung, O Giricz, K Pradhan, K Kataoka, S Gordon-Mitchell, ... Blood, The Journal of the American Society of Hematology 132 (14), 1507-1518, 2018 | 73 | 2018 |
| Epigenetically aberrant stroma in MDS propagates disease via Wnt/β-catenin activation TD Bhagat, S Chen, M Bartenstein, AT Barlowe, D Von Ahrens, ... Cancer research 77 (18), 4846-4857, 2017 | 70 | 2017 |
| Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two … A Abbasi, S Peeke, N Shah, J Mustafa, F Khatun, A Lombardo, M Abreu, ... Journal of hematology & oncology 13, 1-4, 2020 | 69 | 2020 |
| Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity P Msaouel, AP Lam, K Gundabolu, G Chrysofakis, Y Yu, I Mantzaris, ... Haematologica 99 (5), 930, 2014 | 67 | 2014 |
| Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease C Gluck, C Qiu, SY Han, M Palmer, J Park, YA Ko, Y Guan, X Sheng, ... Nature communications 10 (1), 2461, 2019 | 66 | 2019 |
| Thrombopoietin receptor–independent stimulation of hematopoietic stem cells by eltrombopag YR Kao, J Chen, SR Narayanagari, TI Todorova, MM Aivalioti, M Ferreira, ... Science translational medicine 10 (458), eaas9563, 2018 | 64 | 2018 |
| Trastuzumab plus paclitaxel or docetaxel in HER-2–negative/HER-2 ECD–positive anthracycline-and taxane-refractory advanced breast cancer A Ardavanis, P Kountourakis, F Kyriakou, S Malliou, I Mantzaris, ... The Oncologist 13 (4), 361-369, 2008 | 49 | 2008 |
| Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results M Heuser, N Palmisiano, I Mantzaris, A Mims, C DiNardo, LR Silverman, ... Leukemia 34 (11), 2903-2913, 2020 | 46 | 2020 |
| Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia L Bachegowda, K Morrone, SL Winski, I Mantzaris, M Bartenstein, ... Cancer research 76 (16), 4841-4849, 2016 | 42 | 2016 |
| Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy M Zell, A Assal, O Derman, N Kornblum, R Battini, Y Wang, ... Oncotarget 7 (32), 51981, 2016 | 36 | 2016 |
| High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort S Goel, J Hall, K Pradhan, C Hirsch, B Przychodzen, A Shastri, I Mantzaris, ... Leukemia 30 (8), 1793-1795, 2016 | 35 | 2016 |
| Epidemiology and survival trend of adult T‐cell leukemia/lymphoma in the United States UA Shah, N Shah, B Qiao, A Acuna‐Villaorduna, K Pradhan, ... Cancer 126 (3), 567-574, 2020 | 29 | 2020 |
| Results from ongoing phase 2 trial of SL-401 as consolidation therapy in patients with acute myeloid leukemia (AML) in remission with high relapse risk including minimal … AA Lane, KL Sweet, ES Wang, WB Donnellan, RB Walter, AS Stein, ... Blood, The Journal of the American Society of Hematology 128 (22), 215-215, 2016 | 25 | 2016 |
| Multiple myeloma in hispanics: incidence, characteristics, survival, results of discovery, and validation using real-world and connect MM registry data G Kaur, MM Saldarriaga, N Shah, DD Catamero, L Yue, N Ashai, ... Clinical Lymphoma Myeloma and Leukemia 21 (4), e384-e397, 2021 | 22 | 2021 |
| A case series of monoclonal gammopathy of undetermined significance and COVID‐19 JD Gonzalez‐Lugo, L Bachier‐Rodriguez, M Goldfinger, A Shastri, ... British Journal of Haematology 190 (3), e130, 2020 | 21 | 2020 |
